What is Revelation Biosciences, Inc.'s market cap?

Revelation Biosciences, Inc. (REVB) has a market capitalization of $4.1M and trades on NASDAQ.

Who are Revelation Biosciences, Inc.'s competitors?

Revelation Biosciences, Inc.'s key competitors include ProKidney Corp. Class A Ordinary Shares, Akebia Therapeutics, Inc., Travere Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Revelation Biosciences, Inc. partner with?

Revelation Biosciences, Inc.'s notable partners include Vanderbilt University, Avanti Polar Lipids, Inc..

Where is Revelation Biosciences, Inc. headquartered?

Revelation Biosciences, Inc. is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2022.

Revelation Biosciences, Inc.

REVB

Revelation Biosciences is a clinical-stage biopharmaceutical company focused on rebalancing the innate immune system to treat and prevent inflammatory diseases.

Market cap

$4.14M+10.2%

Table of contents

Earnings

Q1 2026 report

May 7, 2026

EPS-$2.71Miss by $1.56

Read the full report

Next report

Aug 7, 2026 (In 1 week)

EPS estimate-$0.83

Competitors

By market cap

Apogee Therapeutics, Inc.$10.2B+339%

Travere Therapeutics, Inc.$5.3B+285%

Eton Pharmaceuticals, Inc.$1.2B+188%

Akebia Therapeutics$343.4M-63.6%

PRO

ProKidney Corp.$316.0M-23.1%

Unicycive Therapeutics, Inc.$140.5M+134%

KYN

Kyntra Bio, Inc.$28.5M—

Revelation Biosciences, Inc.$4.1M+0.4%

By revenue growth

Travere Therapeutics, Inc.+96.0%

Eton Pharmaceuticals, Inc.+79.9%

By net margin

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Travere Therapeutics, Inc.-20.32%+105pp

Profile

Revelation Biosciences is a clinical-stage biopharmaceutical company focused on rebalancing the innate immune system to treat and prevent inflammatory diseases. Its core value proposition centers on Gemini, a proprietary formulation of a Toll-like receptor 4 (TLR4) agonist designed to modulate dysregulated inflammatory responses without inducing excessive pro-inflammatory activity.

Competitive position

A clinical-stage developer targeting significant unmet needs in kidney disease where no approved therapeutic treatments currently exist for acute kidney injury.

GeographiesUnited States

Customer segmentsPatients, Healthcare Providers

Business modelResearch and Development, Licensing

SuppliersContract Manufacturing Organizations, Contract Research Organizations, Active Pharmaceutical Ingredient Suppliers

CustomersPharmaceutical Distributors, Hospitals, Specialty Pharmacies

CountryUnited States of America

Listed2022

Employees9.0

CEOJames Rolke

SectorHealthcare

IndustryBiotechnology

Websiterevbiosciences.com

FilingsSEC EDGAR

Questions, answered.

What is Revelation Biosciences, Inc.'s market cap?: Revelation Biosciences, Inc. (REVB) has a market capitalization of $4.1M and trades on NASDAQ.
Who are Revelation Biosciences, Inc.'s competitors?: Revelation Biosciences, Inc.'s key competitors include ProKidney Corp. Class A Ordinary Shares, Akebia Therapeutics, Inc., Travere Therapeutics, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Revelation Biosciences, Inc. partner with?: Revelation Biosciences, Inc.'s notable partners include Vanderbilt University, Avanti Polar Lipids, Inc..
Where is Revelation Biosciences, Inc. headquartered?: Revelation Biosciences, Inc. is headquartered in United States of America and employs approximately 9 people. It has been publicly traded since 2022.